MODY patients typically present with hyperglycemia and impaired glucose-stimulated insulin secretion (GSIS) by young adulthood, while having normal body weight and lacking β-cell autoimmunity (Fajans and Bell, 2011). This evidence concerns the gene INS and MODY.